-+ 0.00%
-+ 0.00%
-+ 0.00%

ImmunoPrecise's AI-Powered LENSai Platform, Driven By Patented HYFT Technology, Identifies A Highly Conserved Multi-Factorial Epitope Across All Four Dengue Virus Serotypes

Benzinga·06/05/2025 12:09:16
Listen to the news

LENSai™ powered by HYFT® technology Identifies a single multi-factorial target conserved across all dengue serotypes.

ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, announces discovery of a highly conserved epitope across all four dengue virus serotypes using its proprietary LENSai™ platform powered by their patented HYFT® technology. This discovery, made using several proprietary HYFT-based analyses, identifies a part of the virus (an epitope) that has remained unmutated across all four known virus serotypes, therefore potentially allowing an epitope-based vaccine to target and activate the immune system to eliminate the virus. This discovery marks a major milestone toward the development of a potential universal dengue vaccine and validates the Company's newly launched, HYFT pattern-patented AI-native vaccine discovery engine.